SWI/SNF
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
top
In molecular biology, SWI/SNF (SWItch/Sucrose Non-Fermentable),cite-ref-pmid6392017-1-0[1]cite-ref-pmid6436497-2-0[2] is a subfamily of ATP-dependent chromatin remodeling complexes, which is found in eukaryotes. In other words, it is a group of proteins that associate to remodel the way DNA is packaged. This complex is composed of several proteins – products of the SWI and SNF genes (SWI1, SWI2/SNF2, SWI3, SWI5, SWI6), as well as other polypeptides.cite-ref-pmid9118215-3-0[3] It possesses a DNA-stimulated ATPase activity that can destabilize histone-DNA interactions in reconstituted nucleosomes in an ATP-dependent manner, though the exact nature of this structural change is unknown. The SWI/SNF subfamily provides crucial nucleosome rearrangement, which is seen as ejection and/or sliding. The movement of nucleosomes provides easier access to the chromatin, enabling binding of specific transcription factors,cite-ref-4[4] and allowing genes to be activated or repressed.cite-ref-clapier-2017-5-0[5]
The human analogs of SWI/SNF are "BRG1- or BRM-associated factors", or BAF (SWI/SNF-A) and "Polybromo-associated BAF", which is also known as PBAF (SWI/SNF-B).cite-ref-pmid126655912-6-0[6] There are also Drosophila analogs of SWI/SNF, known as "Brahma Associated Protein", or BAP and "Polybromo-associated BAP", also known as PBAP.cite-ref-0-7-0[7]
Contents
• Function
• History
• See also
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
Mechanism of action
It has been found that the SWI/SNF complex (in yeast) is capable of altering the position of nucleosomes along DNA.cite-ref-8[8]cite-ref-pmid10466730-9-0[9] These alterations are classified in three different ways, and they are seen as the processes of sliding nucleosomes, ejecting nucleosomes, and ejecting only certain components of the nucleosome.cite-ref-clapier-2017-5-1[5] Due to the actions performed by the SWI/SNF subfamily, they are referred to as "access remodellers" and promote gene expression by exposing binding sites so that transcription factors can bind more easily.cite-ref-clapier-2017-5-2[5] Two mechanisms for nucleosome remodeling by SWI/SNF have been proposed.cite-ref-pmid12897850-10-0[10] The first model contends that a unidirectional diffusion of a twist defect within the nucleosomal DNA results in a corkscrew-like propagation of DNA over the octamer surface that initiates at the DNA entry site of the nucleosome. The other is known as the "bulge" or "loop-recapture" mechanism and it involves the dissociation of DNA at the edge of the nucleosome with re-association of DNA inside the nucleosome, forming a DNA bulge on the octamer surface. The DNA loop would then propagate across the surface of the histone octamer in a wave-like manner, resulting in the re-positioning of DNA without changes in the total number of histone-DNA contacts.cite-ref-pmid12666181-11-0[11] A recent studycite-ref-pmid16518397-12-0[12] has provided strong evidence against the twist diffusion mechanism and has further strengthened the loop-recapture model.
Role as a tumor suppressor
The mammalian SWI/SNF (mSWI/SNF) complex functions as a tumor suppressor in many human malignant cancers.cite-ref-13[13] Early studies identified that SWI/SNF subunits were frequently absent in cancer cell lines.cite-ref-14[14] SWI/SNF was first identified in 1998 as a tumor suppressor in rhabdoid tumors, a rare pediatric malignant cancer.cite-ref-pmid9671307-15-0[15] Other instances of SWI/SNF acting as a tumor suppressor comes from the heterozygous deletion of BAF47cite-ref-16[16] or alteration of BAF47.cite-ref-17[17] These instances result in cases of chronic and acute CML and in rarer cases, Hodgkin's lymphoma, respectively. To prove that BAF47, also known as SMARCB1, acts as a tumor suppressor, experiments resulting in the formation of rhabdoid tumors in mice were conducted via total knockout of BAF47.cite-ref-18[18] As DNA sequencing costs diminished, many tumors were sequenced for the first time around 2010. Several of these studies revealed SWI/SNF to be a tumor suppressor in a number of diverse malignancies.cite-ref-pmid20942669-19-0[19]cite-ref-pmid21822264-20-0[20]cite-ref-pmid22233809-21-0[21]cite-ref-pmid21248752-22-0[22] Several studies revealed that subunits of the mammalian complex, including ARID1A,cite-ref-23[23] PBRM1,cite-ref-pmid21248752-22-1[22] SMARCB1,cite-ref-24[24] SMARCA4,cite-ref-hodges-2018-25-0[25] and ARID2,cite-ref-pmid21822264-20-1[20] are frequently mutated in human cancers. It has been noted that total loss of BAF47 is extremely rare and instead, most cases of tumors that resulted from SWI/SNF subunits come from BRG1 deletion, BRM deletion, or total loss of both subunits.cite-ref-26[26] Further analysis concluded that total loss of both subunits was present in about 10% of tumor cell lines after 100 cell lines were looked at.cite-ref-27[27] A meta-analysis of many sequencing studies demonstrated SWI/SNF to be mutated in approximately 20% of human malignancies.cite-ref-pmid23355908-28-0[28]
Role as a cancer dependency
The function of the mammalian SWI/SNF complex is highly tissue-specific,cite-ref-29[29] and in addition to its role as a tumor suppressor described above, SWI/SNF complexes also act as dependencies in several different cancer contexts, including acute myeloid leukemia,cite-ref-1-30-0[30]cite-ref-31[31] prostate cancer,cite-ref-2-32-0[32] neuroblastoma,cite-ref-5-33-0[33] uveal melanoma,cite-ref-34[34] synovial sarcoma,cite-ref-35[35] and lung cancer.cite-ref-36[36] Because SWI/SNF complexes are viewed as potentially viable drug targets for treating tumors that depend of SWI/SNF activity,cite-ref-37[37] several programs in the pharmaceutical industrycite-ref-3-38-0[38]cite-ref-4-39-0[39]cite-ref-40[40] and in academic settingscite-ref-41[41]cite-ref-2-32-1[32] have sought to develop inhibitors or protein degraders of the complex. Small molecules that inactivate SWI/SNF complexes by interfering with ATP hydrolysiscite-ref-1-30-1[30]cite-ref-3-38-1[38] or by causing degradation of key protein subunitscite-ref-4-39-1[39] have demonstrated efficacy in pre-clinical studies. Common to many of these settings is the requirement of SWI/SNF activity to promote the expression of genes involved in replication commitment, specifically for the expression of proteins that promote transition between G1 and S phase of the cell cycle.cite-ref-5-33-1[33] This area is rapidly evolving and the development of drugs targeting these complexes is ongoing.
Structure of the SWI/SNF complex
Electron microscopy studies of SWI/SNF and RSC (SWI/SNF-B) reveal large, lobed 1.1-1.3 MDa structures.cite-ref-42[42]cite-ref-leschziner-2007-43-0[43]cite-ref-44[44]cite-ref-45[45] These structures resemble RecA and cover both sides of a conserved section of the ATPase domain. The domain also contains a separate domain, HSA, that is capable of binding actin, and resides on the N-terminus.cite-ref-clapier-2017-5-3[5] The bromo domain present is responsible for recognizing and binding lysines that have been acetylated.cite-ref-0-7-1[7] No atomic-resolution structures of the entire SWI/SNF complex have been obtained to date, due to the protein complex being highly dynamic and composed of many subunits. However, domains and several individual subunits from yeast and mammals have been described. In particular, the cryo-EM structure of the ATPase Snf2 in complex with a nucleosome shows that nucleosomal DNA is locally deformed at the site of binding.cite-ref-46[46] A model of the mammalian ATPase SMARCA4 shows similar features,cite-ref-hodges-2018-25-1[25] based on the high degree of sequence homology with yeast Snf2. The interface between two subunits, BAF155 (SMARCC1) and BAF47 (SMARCB1) was also resolved, providing important insights into the mechanisms of the SWI/SNF complex assembly pathway.cite-ref-47[47]
SWIB/MDM2 protein domain
The protein domain, SWIB/MDM2, short for SWI/SNF complex B/MDM2 is an important domain. This protein domain has been found in both SWI/SNF complex B and in the negative regulator of the p53 tumor suppressor MDM2. It has been shown that MDM2 is homologous to the SWIB complex.cite-ref-pmid12016060-48-0[48]
Function
The primary function of the SWIB protein domain is to aid gene expression. In yeast, this protein domain expresses certain genes, in particular BADH2, GAL1, GAL4, and SUC2. It works by increasing transcription. It has ATPase activity, meaning it breaks down ATP, the basic unit of energy currency. This destabilizes the interaction between DNA and histones. The destabilization that occurs disrupts chromatin and opens up the transcription-binding domains. Transcription factors can then bind to this site, leading to an increase in transcription.cite-ref-pmid11147808-49-0[49]
Protein interaction
The various protein subunits that make up the SWI/SNF complex interact with each other in different configurations to form three distinct types of SWI/SNF complex: canonical BAF (cBAF), polybromo-associated BAF (pBAF) and non-canonical BAF (ncBAF). Specifically, cBAF is currently thought to regulate gene enhancers, while pBAF and ncBAF function at regions proximal to gene promoters.cite-ref-pmid34753942-50-0[50] In addition to their many interactions within the family of SWI/SNF related proteins, some subunits such as SNF5 and BAF155 are capable of interacting with transcription factors, such as c-MYC and the FOS and JUN family proteins of the AP-1 complex.cite-ref-pmid33931740-51-0[51]cite-ref-pmid29272704-52-0[52] In human cells, the interaction of SWI/SNF with multiple transcription factors and co-activators is mediated by binding of the ARID1A subunit with beta-catenin,cite-ref-53[53] which in turn binds a diverse set of binding partners.
Structure
Family members
| Yeast | Human | Drosophila | Function |
|---|---|---|---|
| SWI1 | ARID1A , ARID1B | OSA | Contains LXXLL nuclear receptor binding motifs |
| SWI2 / SNF2 | SMARCA2 , SMARCA4 | BRM | ATP dependent chromatin remodeling |
| SWI3 | SMARCC1 , SMARCC2 | Moira / BAP155 | Similar sequence; function unknown |
| SWP73 / SNF12 | SMARCD1 , SMARCD2 , SMARCD3 | BAP60 | Similar sequence; function unknown |
| SWP61 / ARP7 | ACTL6A , ACTL6B | | Actin -like protein |
| SNF5 | SMARCB1 | SNR1 | ATP dependent chromatin remodeling |
History
The SWI/SNF complex was first discovered in the yeast, Saccharomyces cerevisiae. It was named after initially screening for mutations that would affect the pathways for both yeast mating types switching (SWI) and sucrose non-fermenting (SNF).cite-ref-pmid11147808-49-1[49]cite-ref-0-7-2[7]
See also
References
cite-note-44. ↑ citerefbarisicstadleriurlarosch-beler2019Barisic, Darko; Stadler, Michael B.; Iurlaro, Mario; Schübeler, Dirk (May 2019). "Mammalian ISWI and SWI/SNF selectively mediate binding of distinct transcription factors". Nature. 569 (7754): 136–140. Bibcode:2019Natur.569..136B. doi:10.1038/s41586-019-1115-5. ISSN 1476-4687. PMC 6522387. PMID 30996347.
cite-note-clapier-2017-55. ↑ citerefclapieriwasacairnspeterson2017Clapier CR, Iwasa J, Cairns BR, Peterson CL (July 2017). "Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes". Nature Reviews. Molecular Cell Biology. 18 (7): 407–422. doi:10.1038/nrm.2017.26. PMC 8127953. PMID 28512350.
cite-note-pmid126655912-66. ↑ citerefnieyanchensechi2003Nie Z, Yan Z, Chen EH, Sechi S, Ling C, Zhou S, et al. (April 2003). "Novel SWI/SNF chromatin-remodeling complexes contain a mixed-lineage leukemia chromosomal translocation partner". Molecular and Cellular Biology. 23 (8): 2942–2952. doi:10.1128/MCB.23.8.2942-2952.2003. PMC 152562. PMID 12665591.
cite-note-0-77. ↑ citereftangnogalesciferri2010Tang L, Nogales E, Ciferri C (June 2010). "Structure and function of SWI/SNF chromatin remodeling complexes and mechanistic implications for transcription". Progress in Biophysics and Molecular Biology. 102 (2–3): 122–128. doi:10.1016/j.pbiomolbio.2010.05.001. PMC 2924208. PMID 20493208.
cite-note-pmid10466730-99. ↑ citerefwhitehouseflauscairnswhite1999Whitehouse I, Flaus A, Cairns BR, White MF, Workman JL, Owen-Hughes T (August 1999). "Nucleosome mobilization catalysed by the yeast SWI/SNF complex". Nature. 400 (6746): 784–787. Bibcode:1999Natur.400..784W. doi:10.1038/23506. PMID 10466730. S2CID 2841873.
cite-note-pmid16518397-1212. ↑ citerefzofallpersingerkassabovbartholomew2006Zofall M, Persinger J, Kassabov SR, Bartholomew B (April 2006). "Chromatin remodeling by ISW2 and SWI/SNF requires DNA translocation inside the nucleosome". Nature Structural & Molecular Biology. 13 (4): 339–346. doi:10.1038/nsmb1071. PMID 16518397. S2CID 24163324.
cite-note-1414. ↑ citerefdunaiefstroberguhakhavari1994Dunaief JL, Strober BE, Guha S, Khavari PA, Alin K, Luban J, et al. (October 1994). "The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest". Cell. 79 (1): 119–130. doi:10.1016/0092-8674(94)90405-7. PMID 7923370. S2CID 7058539.
cite-note-pmid9671307-1515. ↑ citerefversteeges-venetlangerousseau-merck1998Versteege I, Sévenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, et al. (July 1998). "Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer". Nature. 394 (6689): 203–206. Bibcode:1998Natur.394..203V. doi:10.1038/28212. PMID 9671307. S2CID 6019090.
cite-note-pmid20942669-1919. ↑ citerefwiegandshahal-aghazhao2010Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. (October 2010). "ARID1A mutations in endometriosis-associated ovarian carcinomas". The New England Journal of Medicine. 363 (16): 1532–1543. doi:10.1056/NEJMoa1008433. PMC 2976679. PMID 20942669.
cite-note-pmid21822264-2020. ↑ citereflizhaozhangwood2011Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, et al. (August 2011). "Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma". Nature Genetics. 43 (9): 828–829. doi:10.1038/ng.903. PMC 3163746. PMID 21822264.
cite-note-pmid22233809-2121. ↑ citerefshaingiacominimatsukumakarikari2012Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, Hidalgo M, et al. (January 2012). "Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer". Proceedings of the National Academy of Sciences of the United States of America. 109 (5): E252 – E259. Bibcode:2012PNAS..109E.252S. doi:10.1073/pnas.1114817109. PMC 3277150. PMID 22233809.
cite-note-pmid21248752-2222. ↑ citerefvarelatarpeyrainehuang2011Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al. (January 2011). "Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma". Nature. 469 (7331): 539–542. Bibcode:2011Natur.469..539V. doi:10.1038/nature09639. PMC 3030920. PMID 21248752.
cite-note-2323. ↑ citerefmathuralversan-romanwilson2017Mathur R, Alver BH, San Roman AK, Wilson BG, Wang X, Agoston AT, et al. (February 2017). "ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice". Nature Genetics. 49 (2): 296–302. doi:10.1038/ng.3744. PMC 5285448. PMID 27941798.
cite-note-2424. ↑ citerefisakoffsansamtamayosubramanian2005Isakoff MS, Sansam CG, Tamayo P, Subramanian A, Evans JA, Fillmore CM, et al. (December 2005). "Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation". Proceedings of the National Academy of Sciences of the United States of America. 102 (49): 17745–17750. Bibcode:2005PNAS..10217745I. doi:10.1073/pnas.0509014102. PMC 1308926. PMID 16301525.
cite-note-hodges-2018-2525. ↑ citerefhodgesstantoncermakovachang2018Hodges HC, Stanton BZ, Cermakova K, Chang CY, Miller EL, Kirkland JG, et al. (January 2018). "Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers". Nature Structural & Molecular Biology. 25 (1): 61–72. doi:10.1038/s41594-017-0007-3. PMC 5909405. PMID 29323272.
cite-note-2727. ↑ citerefdecristofarobetzroriereisman2001Decristofaro MF, Betz BL, Rorie CJ, Reisman DN, Wang W, Weissman BE (January 2001). "Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies". Journal of Cellular Physiology. 186 (1): 136–145. doi:10.1002/1097-4652(200101)186:1<136::aid-jcp1010>3.0.co;2-4. PMID 11147808. S2CID 25016283.
cite-note-2929. ↑ citerefalverkimluwang2017Alver, Burak H.; Kim, Kimberly H.; Lu, Ping; Wang, Xiaofeng; Manchester, Haley E.; Wang, Weishan; Haswell, Jeffrey R.; Park, Peter J.; Roberts, Charles W. M. (2017-03-06). "The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers". Nature Communications. 8 14648. Bibcode:2017NatCo...814648A. doi:10.1038/ncomms14648. ISSN 2041-1723. PMC 5343482. PMID 28262751.
cite-note-1-3030. ↑ citerefchamberscermakovachankurtz2023Chambers, Courtney; Cermakova, Katerina; Chan, Yuen San; Kurtz, Kristen; Wohlan, Katharina; Lewis, Andrew Henry; Wang, Christiana; Pham, Anh; Dejmek, Milan; Sala, Michal; Loeza Cabrera, Mario; Aguilar, Rogelio; Nencka, Radim; Lacorazza, Daniel; Rau, Rachel E. (2023-01-20). "SWI/SNF blockade disrupts PU.1-directed enhancer programs in normal hematopoietic cells and acute myeloid leukemia". Cancer Research. 83 (7): CAN–22–2129. doi:10.1158/0008-5472.CAN-22-2129. ISSN 1538-7445. PMC 10071820. PMID 36662812. S2CID 256031128.
cite-note-3131. ↑ citerefragorodriguesbonneysprouffske2022Rago, Florencia; Rodrigues, Lindsey Ulkus; Bonney, Megan; Sprouffske, Kathleen; Kurth, Esther; Elliott, GiNell; Ambrose, Jessi; Aspesi, Peter; Oborski, Justin; Chen, Julie T.; McDonald, E. Robert; Mapa, Felipa A.; Ruddy, David A.; Kauffmann, Audrey; Abrams, Tinya (2022-03-01). "Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia". Molecular Cancer Research. 20 (3): 361–372. doi:10.1158/1541-7786.MCR-21-0390. ISSN 1557-3125. PMID 34799403. S2CID 244454472.
cite-note-2-3232. ↑ citerefxiaoparoliaqiaobawa2022Xiao, Lanbo; Parolia, Abhijit; Qiao, Yuanyuan; Bawa, Pushpinder; Eyunni, Sanjana; Mannan, Rahul; Carson, Sandra E.; Chang, Yu; Wang, Xiaoju; Zhang, Yuping; Vo, Josh N.; Kregel, Steven; Simko, Stephanie A.; Delekta, Andrew D.; Jaber, Mustapha (January 2022). "Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer". Nature. 601 (7893): 434–439. Bibcode:2022Natur.601..434X. doi:10.1038/s41586-021-04246-z. ISSN 1476-4687. PMC 8770127. PMID 34937944.
cite-note-5-3333. ↑ citerefcermakovataodejmeksala2023Cermakova, Katerina; Tao, Ling; Dejmek, Milan; Sala, Michal; Montierth, Matthew D.; Chan, Yuen San; Patel, Ivanshi; Chambers, Courtney; Loeza Cabrera, Mario; Hoffman, Dane; Parchem, Ronald J.; Wang, Wenyi; Nencka, Radim; Barbieri, Eveline; Hodges, H. Courtney (2023-11-23). "Reactivation of the G1 enhancer landscape underlies core circuitry addiction to SWI/SNF". Nucleic Acids Research. 52 (1): 4–21. doi:10.1093/nar/gkad1081. ISSN 1362-4962. PMC 10783513. PMID 37993417.
cite-note-3434. ↑ citerefragoelliottlisprouffske2020Rago, Florencia; Elliott, GiNell; Li, Ailing; Sprouffske, Kathleen; Kerr, Grainne; Desplat, Aurore; Abramowski, Dorothee; Chen, Julie T.; Farsidjani, Ali; Xiang, Kay X.; Bushold, Geoffrey; Feng, Yun; Shirley, Matthew D.; Bric, Anka; Vattay, Anthony (October 2020). "The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma". Molecular Cancer Therapeutics. 19 (10): 2186–2195. doi:10.1158/1535-7163.MCT-19-1013. ISSN 1538-8514. PMID 32747420. S2CID 222093985.
cite-note-3535. ↑ citerefbrienremillardshihemming2018Brien, Gerard L.; Remillard, David; Shi, Junwei; Hemming, Matthew L.; Chabon, Jonathon; Wynne, Kieran; Dillon, Eugène T.; Cagney, Gerard; Van Mierlo, Guido; Baltissen, Marijke P.; Vermeulen, Michiel; Qi, Jun; Fröhling, Stefan; Gray, Nathanael S.; Bradner, James E. (2018-11-15). "Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma". eLife. 7: e41305. doi:10.7554/eLife.41305. ISSN 2050-084X. PMC 6277197. PMID 30431433.
cite-note-3636. ↑ citereftrejo-villegasirenefederico2024Trejo-Villegas, Octavio A.; Irene, Heijink H.; Federico, Ávila-Moreno (2024-06-22). "Preclinical Evidence in the Assembly of Mammalian SWI/SNF Complexes: Epigenetic Insights and Clinical Perspectives in Human Lung Diseases Therapy". Molecular Therapy. 32 (8): 2470–2488. doi:10.1016/j.ymthe.2024.06.026. ISSN 1525-0016. PMC 11405180. PMID 38910326.
cite-note-3-3838. ↑ citerefpapillonnakajimaadairhempel2018Papillon, Julien P. N.; Nakajima, Katsumasa; Adair, Christopher D.; Hempel, Jonathan; Jouk, Andriana O.; Karki, Rajeshri G.; Mathieu, Simon; Möbitz, Henrik; Ntaganda, Rukundo; Smith, Troy; Visser, Michael; Hill, Susan E.; Hurtado, Felipe Kellermann; Chenail, Gregg; Bhang, Hyo-Eun C. (2018-11-21). "Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers". Journal of Medicinal Chemistry. 61 (22): 10155–10172. doi:10.1021/acs.jmedchem.8b01318. ISSN 1520-4804. PMID 30339381. S2CID 53010943.
cite-note-4-3939. ↑ citerefcantleyyerousseaujanuario2022Cantley, Jennifer; Ye, Xiaofen; Rousseau, Emma; Januario, Tom; Hamman, Brian D.; Rose, Christopher M.; Cheung, Tommy K.; Hinkle, Trent; Soto, Leofal; Quinn, Connor; Harbin, Alicia; Bortolon, Elizabeth; Chen, Xin; Haskell, Roy; Lin, Eva (2022-11-10). "Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers". Nature Communications. 13 (1): 6814. Bibcode:2022NatCo..13.6814C. doi:10.1038/s41467-022-34562-5. ISSN 2041-1723. PMC 9649729. PMID 36357397.
cite-note-4040. ↑ citereffedorovcastextallantowen2015Fedorov, Oleg; Castex, Josefina; Tallant, Cynthia; Owen, Dafydd R.; Martin, Sarah; Aldeghi, Matteo; Monteiro, Octovia; Filippakopoulos, Panagis; Picaud, Sarah; Trzupek, John D.; Gerstenberger, Brian S.; Bountra, Chas; Willmann, Dominica; Wells, Christopher; Philpott, Martin (November 2015). "Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance". Science Advances. 1 (10): e1500723. Bibcode:2015SciA....1E0723F. doi:10.1126/sciadv.1500723. ISSN 2375-2548. PMC 4681344. PMID 26702435.
cite-note-4141. ↑ citereffarnabykoeglroywhitworth2019Farnaby, William; Koegl, Manfred; Roy, Michael J.; Whitworth, Claire; Diers, Emelyne; Trainor, Nicole; Zollman, David; Steurer, Steffen; Karolyi-Oezguer, Jale; Riedmueller, Carina; Gmaschitz, Teresa; Wachter, Johannes; Dank, Christian; Galant, Michael; Sharps, Bernadette (July 2019). "BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design". Nature Chemical Biology. 15 (7): 672–680. doi:10.1038/s41589-019-0294-6. ISSN 1552-4469. PMC 6600871. PMID 31178587.
cite-note-4242. ↑ citerefasturiaschungkornberglorch2002Asturias FJ, Chung WH, Kornberg RD, Lorch Y (October 2002). "Structural analysis of the RSC chromatin-remodeling complex". Proceedings of the National Academy of Sciences of the United States of America. 99 (21): 13477–13480. Bibcode:2002PNAS...9913477A. doi:10.1073/pnas.162504299. PMC 129698. PMID 12368485.
cite-note-leschziner-2007-4343. ↑ citerefleschzinersahawittmeyerzhang2007Leschziner AE, Saha A, Wittmeyer J, Zhang Y, Bustamante C, Cairns BR, Nogales E (March 2007). "Conformational flexibility in the chromatin remodeler RSC observed by electron microscopy and the orthogonal tilt reconstruction method". Proceedings of the National Academy of Sciences of the United States of America. 104 (12): 4913–4918. Bibcode:2007PNAS..104.4913L. doi:10.1073/pnas.0700706104. PMC 1820885. PMID 17360331.
cite-note-4444. ↑ citerefsmithhorowitz-schererflanaganwoodcock2003Smith CL, Horowitz-Scherer R, Flanagan JF, Woodcock CL, Peterson CL (February 2003). "Structural analysis of the yeast SWI/SNF chromatin remodeling complex". Nature Structural Biology. 10 (2): 141–145. doi:10.1038/nsb888. PMID 12524530. S2CID 3140088.
cite-note-4545. ↑ citerefchabanezeokonkwochungzhang2008Chaban Y, Ezeokonkwo C, Chung WH, Zhang F, Kornberg RD, Maier-Davis B, et al. (December 2008). "Structure of a RSC-nucleosome complex and insights into chromatin remodeling". Nature Structural & Molecular Biology. 15 (12): 1272–1277. doi:10.1038/nsmb.1524. PMC 2659406. PMID 19029894.
cite-note-pmid11147808-4949. ↑ citerefdecristofarobetzroriereisman2001Decristofaro MF, Betz BL, Rorie CJ, Reisman DN, Wang W, Weissman BE (January 2001). "Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies". Journal of Cellular Physiology. 186 (1): 136–145. doi:10.1002/1097-4652(200101)186:1<136::AID-JCP1010>3.0.CO;2-4. PMID 11147808. S2CID 25016283.
cite-note-pmid34753942-5050. ↑ citerefpagliaroliporazzicurtisscopa2021Pagliaroli L, Porazzi P, Curtis AT, Scopa C, Mikkers HM, Freund C, et al. (November 2021). "Inability to switch from ARID1A-BAF to ARID1B-BAF impairs exit from pluripotency and commitment towards neural crest formation in ARID1B-related neurodevelopmental disorders". Nature Communications. 12 (1) 6469. Bibcode:2021NatCo..12.6469P. doi:10.1038/s41467-021-26810-x. PMC 8578637. PMID 34753942.
cite-note-pmid33931740-5151. ↑ citerefwoodleyromerwangguarnaccia2021Woodley CM, Romer AS, Wang J, Guarnaccia AD, Elion DL, Maxwell JN, et al. (May 2021). "Multiple interactions of the oncoprotein transcription factor MYC with the SWI/SNF chromatin remodeler". Oncogene. 40 (20): 3593–3609. doi:10.1038/s41388-021-01804-7. PMC 8141032. PMID 33931740.
cite-note-pmid29272704-5252. ↑ citerefvierbuchenlingcowleycouch2017Vierbuchen T, Ling E, Cowley CJ, Couch CH, Wang X, Harmin DA, et al. (December 2017). "AP-1 Transcription Factors and the BAF Complex Mediate Signal-Dependent Enhancer Selection". Molecular Cell. 68 (6): 1067–1082.e12. doi:10.1016/j.molcel.2017.11.026. PMC 5744881. PMID 29272704.
cite-note-5353. ↑ citerefchangaorobinsonwang2025Chan, Yuen San; Gao, Qinyu; Robinson, Sarah A.; Wang, Wenzhi; Filandrova, Ruzena; Weinhold, Lisa-Maria; Cabrera, Mario Loeza; Zhang, Miao; Ambati, Chandra Shekar R.; Lerario, Antonio M.; Putluri, Nagireddy; Kiseljak-Vassiliades, Katja; Wierman, Margaret E.; Habra, Mouhammed Amir; Hammer, Gary D. (2025-07-15). "β-catenin functions as a molecular adapter for disordered cBAF interactions". Molecular Cell: S1097–2765(25)00576–3. doi:10.1016/j.molcel.2025.06.026. ISSN 1097-4164. PMID 40695292.
cite-note-pmid10601972-5555. ↑ citerefcollingwoodurnovwolffe1999Collingwood TN, Urnov FD, Wolffe AP (December 1999). "Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription". Journal of Molecular Endocrinology. 23 (3): 255–275. doi:10.1677/jme.0.0230255. PMID 10601972.
External links